Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Urinary Infections
Intervention: piperacillin/tazobactam (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with
complicated urinary tract infections
Clinical Details
Official title: Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Eligibility
Minimum age: 16 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hospitalized patients over 16 years of age with complicated urinary infection
produced by bacteria that are suspected to be susceptible to treatment with
Piperacillin-tazobactam.
Exclusion Criteria:
- Patients known, or thought to be hypersensitivity to beta-lactams
- Patients with an uncomplicated urinary tract infection
Locations and Contacts
Antequera (Málaga), Spain
Avila, Spain
Barcelona, Spain
Berga (Barcelona), Spain
Caceres, Spain
Castellón, Spain
Ciudad Real, Spain
Cuenca, Spain
Cádiz, Spain
Ferrol, Spain
Granada, Spain
Jaen, Spain
Las Palmas, Spain
Lorca (Murcia), Spain
Lugo, Spain
Lérida, Spain
Madrid, Spain
Osuna (Sevilla), Spain
Palma Mallorca, Spain
Pamplona, Spain
Pontevedra, Spain
Terrasa, Spain
Torrelavega, Spain
Valencia, Spain
Valladolid, Spain
Vitoria, Spain
Zaragoza, Spain
Additional Information
Starting date: June 2004
Last updated: September 24, 2009
|
